Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Relugolix Formulations
NCT02396147Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Primary completion
- Apr 2015
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of relugolix in prostate cancer (PCa) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours and 1 more. Started Mar 2015; status: completed.
02
Drugs
relugolix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02396147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02396147.